hailir(SH:603639)2021-04-27 16:00Financial Performance - Net profit attributable to shareholders increased by 56.48% to CNY 130,915,075.65 year-on-year[7] - Operating revenue rose by 42.19% to CNY 1,125,863,066.84 compared to the same period last year[7] - Basic earnings per share increased by 57.14% to CNY 0.55[7] - The company's operating revenue for Q1 2021 reached ¥1,125,863,066.84, a 42.19% increase compared to ¥791,825,545.53 in the same period last year, primarily driven by increased shipments of active ingredients like prothioconazole[14] - Net profit for Q1 2021 was ¥130,915,075.65, reflecting a 56.48% growth from ¥83,660,911.59 in the previous year, attributed to expanded revenue scale[14] - Total operating revenue for Q1 2021 was ¥1,125,863,066.84, an increase of 42.2% compared to ¥791,825,545.53 in Q1 2020[28] - Net profit for Q1 2021 reached ¥22,831,485.94, up 60.1% compared to ¥14,248,476.99 in Q1 2020[32] - The company’s total comprehensive income for Q1 2021 was ¥22,831,485.94, compared to ¥14,248,476.99 in Q1 2020, indicating strong overall performance[32] Asset and Liability Management - Total assets decreased by 2.92% to CNY 4,187,441,262.00 compared to the end of the previous year[7] - The company's total assets as of March 31, 2021, amounted to ¥4,187,441,262.00, a decrease from ¥4,313,363,396.47 at the end of 2020[22] - The total liabilities decreased to ¥1,439,957,827.76 from ¥1,697,131,813.54 at the end of 2020, indicating improved financial stability[22] - Total liabilities for Q1 2021 were ¥779,482,910.84, down from ¥905,700,103.79 in Q1 2020[25] - The total current liabilities included accounts payable of $369,751,115.36, indicating operational obligations[45] Cash Flow and Liquidity - Cash flow from operating activities turned positive with a net amount of CNY 6,688,395.31, a significant improvement from a negative CNY 50,932,664.94 in the previous year[7] - Cash and cash equivalents increased to ¥615,975,139.12 from ¥507,866,260.75, showing improved liquidity[20] - Cash inflow from operating activities in Q1 2021 was approximately ¥325.21 million, up from ¥225.90 million in Q1 2020, representing a year-over-year increase of 44%[37] - Net cash flow from operating activities in Q1 2021 was negative ¥1.47 million, an improvement from negative ¥91.78 million in Q1 2020[37] - The total cash and cash equivalents at the end of Q1 2021 amounted to ¥548,189,431.86, an increase from ¥390,225,249.29 at the end of Q1 2020[36] Shareholder Information - The number of shareholders reached 10,458, indicating a stable shareholder base[11] - The total equity attributable to shareholders as of January 1, 2021, was approximately ¥2.62 billion, consistent with the previous reporting date[42] Operational Efficiency - Management expenses increased by 33.98% to ¥73,015,303.21, primarily due to provisions for technological upgrades and safety environmental rectification costs[14] - The company incurred sales expenses of ¥4,429,067.71 in Q1 2021, down from ¥6,579,907.53 in Q1 2020, showing improved cost management[31] Research and Development - Research and development expenses for Q1 2021 were ¥43,949,756.23, compared to ¥34,417,382.42 in Q1 2020, reflecting a 27.5% increase[28] - Research and development expenses for Q1 2021 were ¥14,913,253.40, up from ¥12,326,260.81 in Q1 2020, indicating a focus on innovation[31] Future Projects - The company is progressing with the installation of major equipment for its 7,000T water-based formulation project and 23,000T agricultural chemical formulation and fertilizer manufacturing project, which are awaiting acceptance[14] - The company has initiated the construction of a new project under its wholly-owned subsidiary, Qingdao Hengning Biotechnology Co., which began in July 2020 and is progressing normally[15]